White Paper

Performance Validation: HPAPI Containment Testing in A Risk-Based Era

Source: Chargepoint Technology

By Michael Avraam , Global Product Manager

Performance Validation: HPAPI Containment Testing in A Risk-Based Era

A surge in oncology and immune-suppressant therapies and increasing demand for high potency active pharmaceutical ingredients (HPAPIs) is pushing manufacturers to explore innovative containment strategies to meet handling requirements.

As these containment strategies evolve, so too does the role of containment verification. There is a clear need to understand the potential variations in testing and differing interpretations of results.  

This article will discuss the key considerations linked to containment performance testing, data collection methods and the interpretation of results. 

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online